- Spinal cord injury: Using cortical targets to improve motor function
- 43 Disability Protesters outside of Senate Mitch McConnell’s office arrested over proposed severe Medicaid cuts.
- Interaction of reactive astrocytes with type I collagen induces astrocytic scar formation through the integrin–N-cadherin pathway after SCI
- SCI Stem-cell pioneer enters the political field in California
- Patients with Complete Paralysis Show Additional Recovery of Arm, Hand and Finger Function at 9-months After Treatment with Asterias’ AST-OPC1
- Induction of immune tolerance by short-course immunosuppresion after spinal grafting of allogeneic neural precursors in pigs with previous chronic spinal cord traumatic injury.
- Growth Hormone Improves Sensory Function in Complete Spinal Injury
- Promoting targeted reinnervation of phrenic motor neurons and restoration of respiratory function using BDNF after SCI
- New Pathways for Recovery of Function Following Paralysis
- The Impact of combination biologics on treadmill quadrupedal locomotion after spinal cord hemi-contusion in non-human primates
- Breakthrough Regenerative Therapeutics Company Establishes Scientific Advisory Board
- Oxygen improves blood flow, restores more function in spinal cord injuries
- Discovery Offers New Hope to Repair Spinal Cord Injuries
- Robotic platform maximizing gravity-dependent gait interactions to train standing and walking after neurological disorders
- Mayo pushes forward with Neuromodulation Discoveries for SCI
Follow on TwitterMy Tweets
Tag Archives: Neuralstem
Induction of immune tolerance by short-course immunosuppresion after spinal grafting of allogeneic neural precursors in pigs with previous chronic spinal cord traumatic injury.
Current clinical protocols use transient or continuous immunosuppression in patients receiving allogeneic neural precursor grafts for treatment of a variety of neurological diseases, including spinal trauma, stroke or ALS. At present there is no solid evidence, however, that would confirm … Continue reading
I frequently check in to see what’s happening at the Paul Knoepfler Stem Cell blog. His post yesterday took me by complete surprise. Even though SCI isn’t part of the PTT Law, this will be an interesting situation to follow. … Continue reading
Neuralstem Spinal Cord Injury Stem Cell Trial Approved To Commence At University Of California, San Diego (NSI-566 to be Tested in Patients with Chronic Spinal Cord Injury)
Neuralstem, Inc. announced that the Institutional Review Board of the University of California, San Diego, School of Medicine has approved the Phase I safety trial to treat chronic spinal cord injury (cSCI) with its NSI-566 stem cells. The NSI-566/cSCI Phase … Continue reading
Richard Garr, President & CEO of Neuralstem gives his presentation on ‘Understanding the Practicalities of Using Innovative Therapies on Patients’ at the World Stem Cells & Regenerative Medicine Congress 2013.
ROCKVILLE, Md., Jan. 14, 2013 /PRNewswire/ — Neuralstem, Inc. (NYSE MKT: CUR) announced that it received approval from the United States Food and Drug Administration (FDA) to commence a Phase I safety trial of its lead cell therapy candidate, NSI-566, … Continue reading